Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC084CSA in Advanced Malignant Solid Tumors
NCT06231550Phase 1Completed
- Sponsor
- FindCure Biosciences
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FC084CSA in advanced malignant solid tumor, sponsored by FindCure Biosciences. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose and 2 more. Started Mar 2023; status: completed.
02
Drugs
FC084CSA
03
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT06231550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06231550.